COSCIENS Biopharma Inc T.AEZS

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:AEZS - Post by User

COSCIENS Biopharma Inc > Down 13% since merger announced

<< Previous

Bullboard Posts

Next >>

Comment by Hopeforthebeston Jun 12, 2024 11:53am

67 Views

Post# 36084957

RE:Down 13% since merger announced

It is now down to to $9.10 since your post 22% since the annoucement. gagnon HAS TO GO HE IS INCAPABLE OF PROVIDING ANY SHAREHOLDER VALUE. SINCE HE HAS TAKEN CONTROL OF AEZS AND CZO HE HAS NO PROVIDED ANY SHAREHOLDER VALUE ONLY DIRECTOR VALUE IN DRAINING THE COMPANIES HE HAS RUN, CZO, AEZS AND JUVENITE. AT THE RATE WE ARE GOING I FORESEE ANOTHER STOCK SPLIT WITHIN THE NEXT COUPLE MONTHS TO MAINTAIN HIS(AND ONLY HIS) DESIRE TO STAY ON THE NASDUQ.

BYE
BYE
BYE GAGNON COME JULY 16, 2024

<< Previous

Bullboard Posts

Next >>

How to navigate the ups and downs of investing in AI